Immunotherapy for keratinocyte cancers. Part I: Immune-related epidemiology, risk factors, pathogenesis, and immunotherapy management of keratinocyte cancers

Neuner, Romy; Lee, J. A.; Rieger, Kerri E.; Park, Caroline; Colevas, A. Dimitrios; Chang, Anne Lynn S.

doi:10.1016/j.jaad.2022.06.1206

Cited by 3 publications

(2 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median follow-up was 17 months (IQR [12][13][14][15][16][17][18][19][20][21][22][23]. In this study, the objective response (radiologically) was assessed early at 12 weeks, and was observed in 22%, including 3.1% with complete response and 18.8% with partial response (Table 2).…”

Section: Efficacy and Safety Of Anti-pd-1 Immunotherapy As Second-lin...mentioning

confidence: 99%

“…In addition, cancer immunology via the innate and adaptive immune system plays a key role in the development of keratinocyte carcinomas. The PD-1 pathway is a checkpoint that plays a central role in the local immunosuppression in the tumor microenvironment [11,12]. PD-L1 is expressed on tumor and/or immune cells and the programmed cell death receptor-1 (PD-1) is expressed on immune cells, including CD8+ and CD4+ T-cells, B-cells and natural killer cells [11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment

Dessinioti,

Stratigos

2023

Dermatol Pract Concept

View full text Add to dashboard Cite

For patients with advanced BCC, including locally advanced or metastatic BCC not amenable to curative surgery or radiotherapy, hedgehog pathway inhibitors (HHI) vismodegib and sonidegib are approved as first-line systemic treatment. Results from clinical trials highlight that the overall discontinuation rate of HHI treatment varies from 88% to 92% with vismodegib and is approximately 92% with sonidegib, and half of patients will discontinue HHI after approximately 8 to 12 months. The main factors weighing in on the decision to discontinue HHI, include efficacy (tumor response), adverse events and patient decision. In clinical practice, some of the patients that stop HHI may be re-evaluated if the tumor becomes amenable to surgery, or restart HHI at a later time, while others will need to switch to immunotherapy, depending on the reasons for HHI discontinuation. In this review, we revisit the therapeutic decisions considering a switch from HHI to immunotherapy with anti-PD-1 agent cemiplimab and we highlight the place of cemiplimab in the therapeutic ladder for patients with advanced BCC. We discuss the evidence on the efficacy and safety of anti-PD-1 agents as second-line systemic monotherapy, or in combination with other treatments, and the emergence of checkpoint immunotherapy as a neoadjuvant treatment.

show abstract

Section: Efficacy and Safety Of Anti-pd-1 Immunotherapy As Second-lin...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment

Dessinioti,

Stratigos

2023

Dermatol Pract Concept

View full text Add to dashboard Cite

show abstract

Tumor microenvironment-activated theranostic nanozymes for trimodal imaging-guided combined therapy

Hu,

Xu,

et al. 2024

Journal of Colloid and Interface Science

View full text Add to dashboard Cite

Squamous cell carcinoma arising in chronically damaged skin (Marjolin’s Ulcer): still an unmet need in the era of immunotherapy

Miodovnik,

Dolev,

Buchen

et al. 2024

The Oncologist

View full text Add to dashboard Cite

Background Cutaneous squamous cell carcinoma (cSCC) is characterized by a high tumor mutational burden due to solar damage and a favorable response to anti-PD-1 immunotherapy. Yet, we encounter tumors arising in areas with minimal sun exposure, such as cSCC that develops in chronically inflamed skin, also known as Marjolin’s Ulcer (MU). The response of MU-SCC to immunotherapy remains unknown. Methods We performed a retrospective analysis of patients diagnosed with cSCC and treated with cemiplimab or pembrolizumab in a single tertiary medical center. Patients lost to follow up were excluded. Results Of the 84 eligible patients, 9 (11%) had MU-SCC. Of these, 2 (22%) reached partial response (PR), and none reached complete response (CR). In contrast, of the 75 patients with solar damage-related cSCC, 40 had PR (53%), and 20 had CR (26%). The difference between the two subtypes was significant (P < .001). Interestingly, 3 patients with MU-SCC received a second-line chemo-immunotherapy and experienced a partial response that continued for 5 to 21 months. Patients with MU-SCC had a significantly shorter median time to progression (TTP) (1.6 vs 51.6 months, P < .001) and progression-free survival (PFS) (1.6 vs 15.4 months, P < .001). Overall survival (OS) was not significantly shorter (17.4 vs 36.7 months, P = .096). Multivariate analysis confirmed that MU-SCC is an independent risk factor for shorter TTP (HR 5.5, 95% CI 2.2-14.0, P < .001) and PFS (HR 3.5, 95% CI 1.5-8.1, P = .003). Conclusions This study suggests that immunotherapy is less beneficial in SCC-MU. More work is needed to verify our findings and explore other treatment options.

show abstract

Immunotherapy for keratinocyte cancers. Part I: Immune-related epidemiology, risk factors, pathogenesis, and immunotherapy management of keratinocyte cancers

Cited by 3 publications

References 94 publications

Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment

Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment

Tumor microenvironment-activated theranostic nanozymes for trimodal imaging-guided combined therapy

Squamous cell carcinoma arising in chronically damaged skin (Marjolin’s Ulcer): still an unmet need in the era of immunotherapy

Contact Info

Product

Resources

About